Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q1 FY2021 Earnings Presentation
32 slides from Caplin Point Laboratories's earnings presentation, Aug 11, 2020
Slide 1: Corrigendum to Investors Presentation for June, 2020
CAPLIN POINT’ Laboratories BSE Limited Department of Corporate Relationship 1% Floor, New Trade Ring, Rotunda Building, Phiroze jeejeebhoy Towers, Dalal Street, Mumbai — 400 001. Scrip Code: 524742 National Stock Exchange of India Ltd., Department of Corporate Services, Exchange Plaza, 5‘ Floor, C-1
Slide 2: Investor Presentation June, 2020
Investor Presentation June, 2020 Proving Remedies BRINGING SMILES to People C IN : L 2 42 3 1 T N1 9 9 0PL C 0 19 05 3 | BSE: 5 24 7 4 2 | NSE: C APL IPOIN T | ISIN : IN E4 75 E0 1 0 2 6 | DUNS: 8 6 - 1 48 - 4 5 5 6 | WWW. C APLIN POIN T .N ET ©2018, Caplin Point Laboratories Limited – All Rights Re
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Content
Content 1 Q1FY21 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin Headquarter, Chennai 3
Slide 5: Content: Q1FY21 Highlights
Content 1 Q1FY21 Highlights 1.1 Quarter Highlights Robust revenue growth coupled with stable 1.2 margins 1.4 P&L for the Quarter & Year 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin CP-I plant at Suthukeny, Puducherry 4
Slide 6: Quarter Highlights
Quarter Highlights Financial Highlights ► Consolidated Total Revenue up 25% to INR 247 Cr in Q1FY21 vs INR 197 Cr in Q1FY20 ► EBITDA at INR 78 Cr, up 9% YoY compared to INR 72 Cr in Q1FY20 ► EPS grew by ~ 9% from INR 6.64 in Q1FY20 to INR 7.21 in Q1FY21 ► Free Cash Flow stood at INR 86.49 Cr for Q1F
Slide 7: Robust quarterly revenue growth coupled with stable margins
Robust quarterly revenue growth coupled with stable margins Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) 247 55 78 50 72 197 FY19 FY20 Q1FY20 Q1FY21 Q1FY20 Q1FY21 Revenue continues its strong momentum with margins being muted due to increased expenditure as a result of acquisition of subsidia
Slide 8: P&L for the Quarter - Consolidated
P&L for the Quarter - Consolidated Value (INR Cr) Q1FY21 Q1FY20 YoY (%) Q4FY20 QoQ (%) Revenue from Operation 240.08 192.55 24.7% 215.23 11.5% Other Income 6.49 4.47 45.3% 19.63 -66.9% Total Revenue 246.57 197.02 25.1% 234.86 5.0% - Cost of Goods sold 108.80 85.18 27.7% 111.43 -2.4% Gross Profit 131
Slide 9: Content: Understanding Caplin
Content 1 Q1FY21 Highlights 2 Understanding Caplin 2.1 Transformation across the decades 2.2 Caplin’s core business Diversified Product Portfolio with a balanced 2.3 product mix Smart mix of manufacturing and outsourcing; 2.4 Product capacities 2.5 Building Research & Development Capabilities Delive
Slide 10: Transformation across the decades
Transformation across the decades Started first Started outsourcing Work on Injectable commercial from China unit starts shipments to US Listed on Stock Exchange Entered Angola Liquid injectable with unique Stock Entered the Caribbean facility gets USFDA Fidelity investment Incorporation & Sale mode
Slide 11: Our core business – Tapping the untapped markets
Our core business – Tapping the untapped markets Generics and Branded Generics Injectable & Ophthalmic Manufacturing and Export Revenue by Business Segements Generic Branded Generic US 75% 25% Revenue 8%* ~40% Export ~60% Export Headquarters Revenue by Channel Africa LATAM Revenue Revenue 5%* Distri
Slide 12: Diversified Product Portfolio with a changing product mix
Diversified Product Portfolio with a changing product mix Diversified Product Portfolio with zero reliance on single product / Therapy 650+ Pharmaceutical 36 Therapeutic formulations Segments Latest focus towards complex spaces Accounts for larger shelf share 4000+ Products Product mix covers over 6
Slide 13: Smart mix of manufacturing, outsourcing; product capacities
Smart mix of manufacturing, outsourcing; product capacities 40% of the products produced inhouse 60% of the products are outsourced from quality conscious partners in India and China Exports India China 60% 40% Total Annual Product Capacity 1,500 Mn 400 Mn 12 Mn Tablets Capsules Pre-Mix Bags 20 Mn 6
Slide 14: Building Research & Development Capabilities
Building Research & Development Capabilities 5 Dedicated Facilities INR 1.6 bn Capex Expensing R&D Kilo Lab Caplin has 5 dedicated R&D Continuous capex investment of Caplin expenses all R&D expenditure. Kilo Lab for Commercial setups (3 – DSIR approved and 2 over INR 1.6 bn over last 5 years Total R
Slide 15: Delivered Robust Profitable Growth & Returns over the years
Delivered Robust Profitable Growth & Returns over the years Total Revenue EBITDA PAT (INR Cr) 905 (INR Cr) (INR Cr) 215 301 177 668 250 553 145 207 412 96 313 134 255 87 58 177 62 41 39 26 2014 2015 2016 2017 2018 2019 2020 2014 2015 2016 2017 2018 2019 2020 2014 2015 2016 2017 2018 2019 2020 Robust
Slide 16: Content: Growth engines of Caplin
Content 1 Q1FY21 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 2.1 Caplin’s growth engines 2.2 Core business 2.3 US Business 2.4 Scaling up the value chain 2.5 Strong balance sheet 2.6 Entering China 4 Amaris Clinical - CrO Clinic, Chennai Appendix 15
Slide 17: Caplin's growth engines
Caplin’s growth engines Core business to grow at historical pace… Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at above industry-average pace with margins expected to improve with inCreased branded generics business … with US Business to boost t
Slide 18: Core business to grow at historical pace…
01 | Core business to grow at historical pace… Overview Performance LATAM Revenue from LATAM + Africa (INR Cr) No. 1 Indian player in Central America 799 InCreased its LATAM footprint from two countries to 12 countries within a 649 decade 540 Entry into Pharmacy sales through Healthcare portal
Slide 19: Caplin's Healthcare portal facilitated sales during COVID-19
Caplin’s Healthcare portal facilitated sales during uncertain times of COVID-19 18
Slide 20: … with US business to boost the overall growth…
02 | … with US business to boost the overall growth… Overview Injectable plant Inspection history Invested ~Rs.450 Crore in Capex and Opex in the last 5 years through Plant has undergone 3 US FDA and 2 EU GMP audits successfully since 2016 internal acCruals to enter the US and Regulated markets
Slide 21: "Capital Plus" partner for Caplin Steriles Ltd.
“Capital Plus” partner for Caplin Steriles Ltd. Transaction Structure Transaction Details Objective Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio and enhance capacities at Plant. Eight Roads and F-Prime Capital – Fidelity together bring access to a Inv
Slide 22: Market opportunity in US
Market opportunity in US ~$2.0bn $670mn Market size of our products approved and under Market size of our products in Pipeline to be filed over approval and next 2 years Overall market opportunity for Caplin in near future in US is about ~$2.7bn 21
Slide 23: … backed by enhanced value chain…
03 | … backed by enhanced value chain… Our strategic decisions which will help us in scaling up value chain Direct approach Forward Backward Setting up of CrO Plant to Portal integration integration into Proposed extension Direct marketing to CrO wing of Caplin pharmacies and Caplin moves fu
Slide 24: Amaris Clinical - CrO Division of Caplin Point
Amaris Clinical - CrO Division of Caplin Point Amaris Clinical – Highlights High level of data Capex of INR Cost savings 72-bed state of integrity compliance 29 Cr. internally of ~50% the art facility through end to end acCrued automation Technologically advanced Commenced volunteer tracking and ope
Slide 25: … Strong balance sheet and…
04 | … Strong balance sheet and… Caplin’s strong balance sheet acts as a anchor for it’s vision of perceiving an ‘Invisible opportunity’ Receivable Days Total Capex Spends in INR Cr Fixed Asset Turnover Ratio 95 3.45 84 89 76.8 3.36 3.25 65.2 2.57 2.71 2.34 46.6 48.5 1.86 30 25.5 25.6 8 12 8.3 0 FY1
Slide 26: … Expansion into other geographies
05 | … Expansion into other geographies Caplin has made a strategic decision to enter lucrative developed markets with its US portfolio and other countries in LATAM market with its wide generics LATAM portfolio Countries Caplin plans to expand its presence Entering china remains our long term target
Slide 27: Content: More about Caplin
Content 1 Q1FY21 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin 4.1 Experienced and visionary BOD & Management 4.2 Shareholder Information R&D centre 26
Slide 28: Experienced and visionary BOD & Management
Experienced and visionary BOD & Management Mr. C.C. Paarthipan Dr. Sridhar Ganesan Mr. D.P. Mishra Dr. K.C. John Chairman Managing Director Director Independent Director 30+ Years of experience in 35+ Years experience in 30+ years experience in the 30+ years experience in the pharmaceutical
Slide 29: Experienced and visionary BOD & Management (cont'd)
Experienced and visionary BOD & Management (cont’d) Dr R Ravichandran D Sathyanarayanan Dr. C K Gariyali, IAS Mr V Thirumalai R Viswanathan Independent Director Independent Director Independent Director Independent Director Independent Director Management and Finance 30+ years experience in Re
Slide 30: Shareholder Information
Shareholder Information Caplin Shareholding as on 30th June 2020 Share Information (as on 30th June 2020) NSE Ticker CAPLIPOINT BSE Ticker 524742 Non-Institutional 27.83% Market Cap (INR Cr) 2,363 % free-float 30.97% Free-float market cap (INR Cr) 732 Total Debt (INR Cr) 29.1 Institution 3.14% Cash
Slide 31: Our Products
Our Products Caplin Point Laboratories Limited a |
Slide 32: Investor Relations at Caplin
Investor Relations at Caplin Vinod Kumar +91 44 24968119 investors@caplinpoint.net 52474 2 CAPLIPO INT CAPL.N S © 2018 Caplin Point Laboratories Limited, All Rights Reserved. “Caplin Point” and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, da
Caplin Point Laboratories — Q1 FY2021 Earnings Presentation on 6ix